Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Feb 28, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Feb 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulatory
TL;DR
Keros Therapeutics filed a standard 8-K on Feb 28, 2025. No major news.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on February 28, 2025, reporting on Regulation FD disclosures and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing serves as a routine disclosure for Keros Therapeutics, Inc., informing the public about regulatory compliance and financial reporting status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K and does not disclose any new material events, risks, or financial information.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- February 28, 2025 (date) — Date of earliest event reported
- 001-39264 (company) — SEC File Number
- 81-1173868 (company) — I.R.S. Employer Identification No.
- Lexington, Massachusetts (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures and to provide financial statements and exhibits as of February 28, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Keros Therapeutics, Inc.
In which state was Keros Therapeutics, Inc. incorporated?
Keros Therapeutics, Inc. was incorporated in Delaware.
What is the address of Keros Therapeutics, Inc.'s principal executive offices?
The address of Keros Therapeutics, Inc.'s principal executive offices is 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the filing date for this 8-K report?
The filing date for this 8-K report is February 28, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 28, 2025 regarding Keros Therapeutics, Inc. (KROS).